Bayer, Orion win FDA priority review for darolutamide in prostate cancer
admin 1st May 2019 Uncategorised 0Darolutamide is an investigational, non-steroidal androgen receptor antagonist.
More: Bayer, Orion win FDA priority review for darolutamide in prostate cancer
Source: News
